Heart failure with preserved left ventricular ejection fraction (HFpEF) is an ongoing challenge. It has been recognized as a substantial clinical problem for over 25 years now. 1 Even though the increasing significance of the disease can be traced throughout subsequent iterations of heart failure guidelines, there are still difficulties in proper and prompt diagnosis, doubts regarding the right management, troubles in finding outcome-improving treatments.
For the patient the ability to successfully contract the left ventricle is relatively insignificant. What matters are the symptoms, often impairing day-to-day life as much as for patients with significantly reduced left ventricular contractility; even more so given that the profile of HFpEF patients has a somewhat different aetiological profile, significantly related to age and multimorbidity. Thus, the problem of heart failure symptoms may be even more cumbersome, as HFpEF patients have been shown to have poor quality of life. 2 Delayed diagnosis, within the spectrum of other diseases, may lead to lack of treatment and further degradation of cardiovascular condition. The patient may find some solace in the fact that the overall prognosis is generally better in HFpEF. 3 The analysis by Gohar et al. presents a potentially useful sex-specific tool for the establishment of working diagnosis of HFpEF in a general population of both symptomatic and asymptomatic patients. The tool is designed to facilitate the decision-making process in primary care units. 4 This may be useful as both overdiagnoses and under-diagnoses have been reported. 5, 6 The availability of guideline-recommended N-terminal pro-brain natriuretic peptide (NT-pro BNP)/BNP is scarce in primary care units, echocardiography even more so. Careful selection of patients referred for further testing is important for many reasons, among which the profound cost of heart failure management cannot be undervalued. In the United States alone the expenditure on heart failure is expected to exceed US$50bn by 2030. 7 From a cardiologist standpoint the 'to do' list is relatively short. Normal natriuretic peptides in a de novo patient practically rule out heart failure diagnosis. 8 The echocardiographic grounds for confirmation of the diagnosis have been described elsewhere on numerous occasions. 9 Cardiopulmonary exercise testing might be considered for risk stratification; however, this does not yet represent standard of care. 10 How to treat, then? It needs to be stressed that no treatment to date has been convincingly shown to improve morbidity and mortality in this population. This statement seems unacceptable in the outcome-centred contemporary cardiology. Some evidence shows that nebivolol, spironolactone, candesartan and digoxin might reduce hospitalizations. A recent post-hoc analysis of the TOPCAT trial suggests for the first time that reninangiotensin system inhibitors in HFpEF patients with mild to moderate chronic kidney disease might improve all-cause mortality. 11 Despite the lack of clear evidence for improvement of overall prognosis, rather unexpectedly empagliflozin has been shown to reduce cardiovascular mortality and heart failure hospitalizations -an important insight, especially since diabetes is among the most important aetiologic factors of HFpEF. 12 Nonetheless, to treat is also to alleviate symptoms. Diuretics will improve symptoms and signs, consistently through all types of heart failure, regardless of left ventricular ejection fraction. Evidence is lacking for the effectiveness of drugs utilized in symptomatic heart failure with reduced ejection fraction -angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers (with the exclusion of candesartan, shown to improve New York Heart Association classification), beta-blockers, mineralocorticoid receptor antagonists. Their utilization should be considered, however, in treatment of the underlying cause of HFpEF and comorbidities. Also, there have been interesting preliminary insights into the impact of home-based rehabilitation on functional capacity; currently there is an aim to begin a randomized trial. 13 With all these in consideration, population-based screening models, such as presented by Gohar et al., are important for the diagnosis of HFpEF. On the other hand, screening for asymptomatic individuals in a subset of patients where we can only improve symptoms seems futile. The argument for stringent management of comorbidities is correct; however, there is no explanation of lack of proper treatment of diseases such as hypertension, diabetes or ischaemic heart disease, regardless of the presence of left ventricular diastolic dysfunction.
In the analysis by Gohar et al. the proposed screening model was analysed with and without the inclusion of NT-pro BNP. Should the adoption of NT-pro BNP in primary care units be wider? This would hardly be a novel concept.
14 However, wider adoption did not occur, mostly due to economic considerations. The negative predictive value of NT-pro BNP would surely be sufficient to deal with over-diagnosis of heart failure and the relatively small proportion of false-positive results be verified after referral to the cardiologist, perhaps rendering additional riskscores unnecessary. Second, it is noticeable that the proposed model is much more complex for male patients. In females the risk model -although beyond any doubt statistically accurate -includes only age, comorbidities and prior beta-blocker treatment. The notion that a multi-morbid elderly female on beta-blockers has high risk of heart failure is perhaps just good clinical judgment and may not require a risk score.
In conclusion, the opportunistic screening model proposed by Gohar et al. shows a complex and profound statistical approach to detecting diastolic dysfunction of the left ventricle and may be useful in certain clinical and administrative scenarios. It would be interesting to see a randomized study comparing the diagnostic accuracy and potential clinical benefit in patients referred to further testing with the use of the proposed tool versus best clinical judgment of attending physician, especially with regard to the sex-specific approach selected by the authors.
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